The treatment of depressive disorders in epilepsy

What all neurologists should know

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

One of every three patients with epilepsy (PWE) will experience a depressive disorder in the course of their life, often associated with anxiety symptoms or a full blown anxiety disorder. Clearly, the high prevalence of these psychiatric comorbidities calls for their early identification and management. This article provides practical strategies in the management of depressive episodes in PWE. Contrary to long-held beliefs, the use of antidepressant drugs are safe in PWE when used at therapeutic doses. Antidepressant drugs of the selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) families are the first line of therapy in depressive disorders, and failure to achieve complete symptom remission after a trial of an SSRI or SNRI at optimal doses should be followed by a second trial with a drug from the other antidepressant family. In developing countries, antidepressant drugs of these two antidepressant families are not always available, and tricyclic antidepressants (TCAs) are the drugs of choice. Although there are no differences in efficacy among the three families of antidepressants, TCAs have a lower tolerability and higher toxicity, with greater mortality risk associated with cardiotoxic effects in overdoses. Cognitive behavior therapy is another treatment modality that has been shown to be effective in the treatment of depressive disorders in patients with and without epilepsy. Its use should be considered together with pharmacotherapy or by itself.

Original languageEnglish (US)
Pages (from-to)3-12
Number of pages10
JournalEpilepsia
Volume54
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2013

Fingerprint

Depressive Disorder
Antidepressive Agents
Epilepsy
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Therapeutics
Cognitive Therapy
Anxiety Disorders
Developing Countries
Psychiatry
Neurologists
Comorbidity
Anxiety
Drug Therapy
Mortality

Keywords

  • Anxiety disorder
  • Cognitive behavior therapy
  • Interictal dysphoric disorder
  • Major depressive episode
  • Selective serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

The treatment of depressive disorders in epilepsy : What all neurologists should know. / Kanner, Andres M.

In: Epilepsia, Vol. 54, No. SUPPL. 1, 03.2013, p. 3-12.

Research output: Contribution to journalArticle

@article{e3900e47f34a40d2995868941eb36e9c,
title = "The treatment of depressive disorders in epilepsy: What all neurologists should know",
abstract = "One of every three patients with epilepsy (PWE) will experience a depressive disorder in the course of their life, often associated with anxiety symptoms or a full blown anxiety disorder. Clearly, the high prevalence of these psychiatric comorbidities calls for their early identification and management. This article provides practical strategies in the management of depressive episodes in PWE. Contrary to long-held beliefs, the use of antidepressant drugs are safe in PWE when used at therapeutic doses. Antidepressant drugs of the selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) families are the first line of therapy in depressive disorders, and failure to achieve complete symptom remission after a trial of an SSRI or SNRI at optimal doses should be followed by a second trial with a drug from the other antidepressant family. In developing countries, antidepressant drugs of these two antidepressant families are not always available, and tricyclic antidepressants (TCAs) are the drugs of choice. Although there are no differences in efficacy among the three families of antidepressants, TCAs have a lower tolerability and higher toxicity, with greater mortality risk associated with cardiotoxic effects in overdoses. Cognitive behavior therapy is another treatment modality that has been shown to be effective in the treatment of depressive disorders in patients with and without epilepsy. Its use should be considered together with pharmacotherapy or by itself.",
keywords = "Anxiety disorder, Cognitive behavior therapy, Interictal dysphoric disorder, Major depressive episode, Selective serotonin reuptake inhibitors",
author = "Kanner, {Andres M}",
year = "2013",
month = "3",
doi = "10.1111/epi.12100",
language = "English (US)",
volume = "54",
pages = "3--12",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The treatment of depressive disorders in epilepsy

T2 - What all neurologists should know

AU - Kanner, Andres M

PY - 2013/3

Y1 - 2013/3

N2 - One of every three patients with epilepsy (PWE) will experience a depressive disorder in the course of their life, often associated with anxiety symptoms or a full blown anxiety disorder. Clearly, the high prevalence of these psychiatric comorbidities calls for their early identification and management. This article provides practical strategies in the management of depressive episodes in PWE. Contrary to long-held beliefs, the use of antidepressant drugs are safe in PWE when used at therapeutic doses. Antidepressant drugs of the selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) families are the first line of therapy in depressive disorders, and failure to achieve complete symptom remission after a trial of an SSRI or SNRI at optimal doses should be followed by a second trial with a drug from the other antidepressant family. In developing countries, antidepressant drugs of these two antidepressant families are not always available, and tricyclic antidepressants (TCAs) are the drugs of choice. Although there are no differences in efficacy among the three families of antidepressants, TCAs have a lower tolerability and higher toxicity, with greater mortality risk associated with cardiotoxic effects in overdoses. Cognitive behavior therapy is another treatment modality that has been shown to be effective in the treatment of depressive disorders in patients with and without epilepsy. Its use should be considered together with pharmacotherapy or by itself.

AB - One of every three patients with epilepsy (PWE) will experience a depressive disorder in the course of their life, often associated with anxiety symptoms or a full blown anxiety disorder. Clearly, the high prevalence of these psychiatric comorbidities calls for their early identification and management. This article provides practical strategies in the management of depressive episodes in PWE. Contrary to long-held beliefs, the use of antidepressant drugs are safe in PWE when used at therapeutic doses. Antidepressant drugs of the selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) families are the first line of therapy in depressive disorders, and failure to achieve complete symptom remission after a trial of an SSRI or SNRI at optimal doses should be followed by a second trial with a drug from the other antidepressant family. In developing countries, antidepressant drugs of these two antidepressant families are not always available, and tricyclic antidepressants (TCAs) are the drugs of choice. Although there are no differences in efficacy among the three families of antidepressants, TCAs have a lower tolerability and higher toxicity, with greater mortality risk associated with cardiotoxic effects in overdoses. Cognitive behavior therapy is another treatment modality that has been shown to be effective in the treatment of depressive disorders in patients with and without epilepsy. Its use should be considered together with pharmacotherapy or by itself.

KW - Anxiety disorder

KW - Cognitive behavior therapy

KW - Interictal dysphoric disorder

KW - Major depressive episode

KW - Selective serotonin reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84874744643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874744643&partnerID=8YFLogxK

U2 - 10.1111/epi.12100

DO - 10.1111/epi.12100

M3 - Article

VL - 54

SP - 3

EP - 12

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 1

ER -